Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoketang is a Traditional Chinese Medicine (TCM) formula traditionally used to treat "Xiao Ke" (wasting-thirst syndrome), which corresponds to diabetes mellitus in modern medicine. In clinical research conducted by the Shanghai Traditional Chinese Medicine Hospital, Xiaoketang is being investigated for its potential therapeutic benefits in patients with diabetic nephropathy, often as an adjunctive therapy to standard treatments like valsartan. The mechanism of action is hypothesized to involve the protection of renal podocytes by modulating the expression of key structural proteins such as Nephrin and Podocin. Additionally, Xiaoketang is studied for its ability to inhibit histone deacetylase (HDAC) activity, which may contribute to the reduction of proteinuria and the preservation of renal function in diabetic patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoketang.